Insider Selling: Aura Biosciences (NASDAQ:AURA) Insider Sells 17,109 Shares of Stock

Aura Biosciences insider Janet Jill Hopkins sold 17,109 shares at $5.42 each, totaling $92,730.78. Post-sale, she owns 252,685 shares, valued at $1,369,552.70, marking a 6.34% decrease in her position. The transaction was disclosed in an SEC filing. Aura Biosciences stock opened at $5.50, with a market cap of $349.25 million. Analysts have mixed ratings, with an average target price of $20.50.

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Janet Jill Hopkins sold 17,109 shares of Aura Biosciences stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $5.42, for a total value of $92,730.78. Following the completion of the sale, the insider owned 252,685 shares of the company's stock, valued at approximately $1,369,552.70. The trade was a 6.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Aura Biosciences Trading Down 0.5%

3 Small-Cap Stocks Ready to Deliver Significant Growth

Shares of NASDAQ:AURA opened at $5.50 on Tuesday. Aura Biosciences, Inc. has a 1-year low of $4.34 and a 1-year high of $9.78. The stock has a market capitalization of $349.25 million, a P/E ratio of -2.84 and a beta of 0.45. The business has a 50-day moving average price of $5.99 and a two-hundred day moving average price of $6.23.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.06. As a group, equities analysts predict that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AURA. Frazier Life Sciences Management L.P. acquired a new stake in Aura Biosciences in the 2nd quarter valued at $31,926,000. Long Focus Capital Management LLC boosted its stake in shares of Aura Biosciences by 30.8% during the 1st quarter. Long Focus Capital Management LLC now owns 3,319,582 shares of the company's stock worth $19,453,000 after buying an additional 781,808 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Aura Biosciences by 16.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company's stock valued at $17,863,000 after acquiring an additional 413,001 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Aura Biosciences by 5.9% in the second quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company's stock valued at $14,653,000 after acquiring an additional 130,221 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its holdings in Aura Biosciences by 67.1% during the second quarter. Nantahala Capital Management LLC now owns 2,117,697 shares of the company's stock worth $13,257,000 after acquiring an additional 850,000 shares in the last quarter. Institutional investors own 96.75% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on AURA shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aura Biosciences in a research report on Tuesday, November 11th. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Wednesday, August 13th. Finally, Zacks Research raised Aura Biosciences from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Aura Biosciences presently has an average rating of "Moderate Buy" and an average target price of $20.50.

Get Our Latest Analysis on Aura Biosciences

Aura Biosciences Company Profile

(Get Free Report)

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.